|1.||Jessen, Michael E: 2 articles (10/2013 - 07/2012)|
|2.||Abd-Elfattah, Anwar Saad: 2 articles (10/2013 - 07/2012)|
|3.||Wechsler, Andrew S: 2 articles (10/2013 - 07/2012)|
|4.||Sanhueza, Felipe: 2 articles (07/2005 - 10/2004)|
|5.||Sobrevia, Luis: 2 articles (07/2005 - 10/2004)|
|6.||González, Marcelo: 2 articles (07/2005 - 10/2004)|
|7.||Casanello, Paola: 2 articles (07/2005 - 10/2004)|
|8.||San Martín, Rody: 2 articles (07/2005 - 10/2004)|
|9.||Siebel, Anna Maria: 1 article (04/2015)|
|10.||Menezes, Fabiano Peres: 1 article (04/2015)|
06/15/1990 - "L1210 murine leukemia cells have two nucleoside transport activities that differ in their sensitivity to nitrobenzylmercaptopurine riboside (NBMPR). "
09/25/1988 - "L1210 mouse leukemia cells exhibit two distinct types of nucleoside transport activity that have similar kinetic properties and substrate specificity, but differ markedly in their sensitivity to the inhibitor nitrobenzylthioinosine (NBMPR) (Belt, J. "
02/01/1982 - "Finally, low araC transport rates or few NBMPR binding sites on blasts were observed in a subset of patients with acute leukemia who failed to achieve remission with drug combinations containing araC."
07/01/1997 - "When the cytotoxicity of a single concentration of araC was determined in NBMPR-treated leukemia cells, cell kill correlated closely with the intensity of 5-(Sx8)-F fluorescence (r = .92 to .99), a measure of the cell surface abundance of functional es nucleoside transporter sites. "
01/01/1991 - "HL-60 leukemia cells, induced to differentiate, activate a Na(+)-dependent nucleoside transport system, concomitant with a reduction in the nitrobenzylthioinosine (NBMPR)-sensitive facilitated transport of nucleosides. "
02/01/1989 - "In this study the density of nucleoside transporters in freshly-isolated blast cells from patients with leukaemias and lymphomas was quantitated by equilibrium binding of 3H-nitrobenzylmercaptopurine riboside (NBMPR). "
10/29/1984 - "This study showed that [3H]NBMPR molecules reversibly bound to intact S49 and L5178Y mouse lymphoma cells became covalently bound upon exposure to UV light. "
01/01/1986 - "From a mutagenized population of wildtype S49 T lymphoma cells, clones were generated that were resistant to the physiological effects of the potent inhibitor of nucleoside transport, 4-nitrobenzyl-6-thioinosine (NBMPR). "
05/25/1985 - "From a mutagenized population of wild type S49 T lymphoma cells, clones were generated that were resistant to the physiological effects of the potent inhibitor of nucleoside transport, 4-nitrobenzyl-6-thioinosine (NBMPR). "
08/01/1988 - "MAb 65D4 also bound to erythrocytes of mice and neonatal pigs and to a variety of cultured cells (mouse, human, rat), including AE1 mouse lymphoma cells, which lack an NBMPR-sensitive nucleoside transporter. "
01/01/1993 - "The majority of tumor cells examined, however, fall between these extremes, and it is not yet known what level of NBMPR-insensitive transport activity can be tolerated without seriously compromising this therapeutic approach. "
01/01/1990 - "It is concluded that there is a mild tumor-sparing effect when either NBMPR or ACT are administered together with single i.v. diagnostic doses of [125I]IUdR."
01/01/1990 - "ACT or NBMPR-P (a water-soluble prodrug of NBMPR) were injected into BDF1 mice bearing implanted Lewis lung tumors, according to protocols which would provide high and low plasma levels of the inhibitor. "
10/15/1984 - "PALA, 150 mg/kg daily X 4, plus NBMPR, 50 or 100 mg/kg daily X 4, resulted in a 6-day tumor growth delay also. "
11/30/2001 - "Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs."
|4.||Hepatocellular Carcinoma (Hepatoma)
06/15/1986 - "The present study showed that nucleoside transport in Novikoff UA rat hepatoma cells is insensitive to site-saturating concentrations of NBMPR. "
08/01/1996 - "Under the same experimental conditions, NBTI effectively blocks most of the Na(+)-independent uridine uptake in hepatoma cells. "
10/20/1992 - "None of the NBTI derivatives significantly inhibited NBTI-resistant equilibrative formycin B transport in P388 and Novikoff rat hepatoma cells at concentrations of < or = 1 microM."
06/27/1985 - "Uridine transport in a variant (NRM) of Novikoff hepatoma cells, in HTC rat hepatoma cells, normal rat kidney (NRK) cells, rat erythrocytes and rat hepatocytes was inhibited 15-60% by 10-500 nM NBTI and the cells expressed high-affinity NBTI-binding sites (Kd = 0.1-0.6 nM). "
06/27/1985 - "Cultured Novikoff rat hepatoma and Walker 256 carcinoma cells have previously been reported to express only nitrobenzylthioinosine (NBTI)-resistant uridine transport and to lack high affinity NBTI-binding sites, whereas the latter are common on all other types of cultured mammalian cells from different species [1-7) X 10(5) sites/cell) which have been investigated with the exception of a transport-deficient cell variant which lacks high-affinity NBTI-binding sites. "
05/01/2014 - "Animal infection studies demonstrated that NBTI 5463 was efficacious in mouse models of lung, thigh, and ascending urinary tract infections. "
05/01/1990 - "In the man and baboon the derivatives had IC50 values in the same order of magnitude as NBMPR (less than 100 nM), and in the rabbit they had potencies close to that of NBMPR, ranging between 10-60 nM. Nucleoside transport inhibitors are of potential importance as host protectors during treatment of parasitic infections with cytotoxic nucleosides. "
10/01/2003 - "Furthermore, infection with a Toxoplasma mutant deficient in parasite adenosine/purine nucleoside transport reduced or abolished the uptake of beta-D-adenosine, NBMPR, and purine beta-L-nucleosides. "
|8.||Adenosine Triphosphate (ATP)
|1.||Drug Therapy (Chemotherapy)
|2.||Cardiopulmonary Bypass (Heart-Lung Bypass)
|4.||Blood Component Transfusion
|5.||Induced Heart Arrest (Cardioplegia)